Alpha Omega Wealth Management LLC Sells 257 Shares of Abbott Laboratories (NYSE:ABT)

Alpha Omega Wealth Management LLC reduced its stake in shares of Abbott Laboratories (NYSE:ABT) by 1.1% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 22,596 shares of the healthcare product maker’s stock after selling 257 shares during the quarter. Alpha Omega Wealth Management LLC’s holdings in Abbott Laboratories were worth $2,348,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Alliance Wealth Advisors LLC UT grew its stake in shares of Abbott Laboratories by 0.4% in the fourth quarter. Alliance Wealth Advisors LLC UT now owns 25,085 shares of the healthcare product maker’s stock worth $2,761,000 after purchasing an additional 92 shares during the last quarter. Wynn Capital LLC grew its stake in shares of Abbott Laboratories by 2.9% in the first quarter. Wynn Capital LLC now owns 3,427 shares of the healthcare product maker’s stock worth $390,000 after purchasing an additional 98 shares during the last quarter. Berger Financial Group Inc grew its stake in shares of Abbott Laboratories by 3.0% in the fourth quarter. Berger Financial Group Inc now owns 3,423 shares of the healthcare product maker’s stock worth $377,000 after purchasing an additional 99 shares during the last quarter. Duff & Phelps Investment Management Co. grew its stake in shares of Abbott Laboratories by 0.5% in the fourth quarter. Duff & Phelps Investment Management Co. now owns 19,280 shares of the healthcare product maker’s stock worth $2,122,000 after purchasing an additional 100 shares during the last quarter. Finally, Bfsg LLC grew its stake in shares of Abbott Laboratories by 21.4% in the first quarter. Bfsg LLC now owns 567 shares of the healthcare product maker’s stock worth $64,000 after purchasing an additional 100 shares during the last quarter. 75.18% of the stock is owned by institutional investors.

Abbott Laboratories Stock Up 0.0 %

Shares of Abbott Laboratories stock traded up $0.02 on Monday, reaching $112.71. The company’s stock had a trading volume of 3,212,680 shares, compared to its average volume of 5,963,927. The company has a market capitalization of $196.07 billion, a price-to-earnings ratio of 35.11, a P/E/G ratio of 2.74 and a beta of 0.72. The firm’s fifty day simple moving average is $106.34 and its two-hundred day simple moving average is $108.68. Abbott Laboratories has a 52 week low of $89.67 and a 52 week high of $121.64. The company has a quick ratio of 1.11, a current ratio of 1.68 and a debt-to-equity ratio of 0.33.

Abbott Laboratories (NYSE:ABT) last posted its earnings results on Thursday, July 18th. The healthcare product maker reported $1.14 EPS for the quarter, topping analysts’ consensus estimates of $1.10 by $0.04. The business had revenue of $10.38 billion during the quarter, compared to analyst estimates of $10.37 billion. Abbott Laboratories had a return on equity of 20.18% and a net margin of 13.65%. The company’s quarterly revenue was up 4.0% compared to the same quarter last year. During the same quarter last year, the company earned $1.08 EPS. Equities analysts anticipate that Abbott Laboratories will post 4.66 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Thursday, August 15th. Investors of record on Monday, July 15th were issued a $0.55 dividend. This represents a $2.20 annualized dividend and a dividend yield of 1.95%. The ex-dividend date was Monday, July 15th. Abbott Laboratories’s payout ratio is currently 68.54%.

Analyst Ratings Changes

Several research firms recently issued reports on ABT. Edward Jones cut Abbott Laboratories from a “buy” rating to a “hold” rating in a research note on Tuesday, July 30th. Barclays upped their target price on Abbott Laboratories from $140.00 to $143.00 and gave the stock an “overweight” rating in a report on Monday, July 29th. Evercore ISI lowered their target price on Abbott Laboratories from $125.00 to $120.00 and set an “outperform” rating for the company in a research note on Tuesday, July 2nd. Royal Bank of Canada restated an “outperform” rating and issued a $125.00 target price on shares of Abbott Laboratories in a research note on Tuesday, June 4th. Finally, The Goldman Sachs Group assumed coverage on Abbott Laboratories in a research note on Thursday, May 30th. They issued a “buy” rating and a $121.00 target price for the company. Two analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $121.80.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.